<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964637</url>
  </required_header>
  <id_info>
    <org_study_id>14-8398-A</org_study_id>
    <nct_id>NCT02964637</nct_id>
  </id_info>
  <brief_title>Diagnosing Frontotemporal Lobar Degeneration</brief_title>
  <official_title>Multimodal Assessment For Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish diagnostic tools to make an accurate clinical and pathological diagnosis of
      patients with clinical FTLD syndromes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to determine the best diagnostic test for diagnosing frontotemporal
      lobar degeneration. To accomplish this, the current study will evaluate different tests:
      brain imaging, skin biopsy, body fluid samples (blood and cerebrospinal fluid), thinking
      abilities, everyday functioning, and brain autopsy. The study team hopes that this
      information can be used to guide diagnosis and further understanding of mechanism of disease
      in Frontotemporal Lobar Degeneration and possibly treatment in the future.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Structural and Functional Diffferences between the FTLD groups via MRI of the brain</measure>
    <time_frame>One time visit through study completion of 5 years</time_frame>
    <description>Differences in brain volumes and resting state functional connectivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences between the FTLD groups via PET imaging of the brain</measure>
    <time_frame>One time visit through study completion of 5 years</time_frame>
    <description>Differences in ligand uptake</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Corticobasal Syndrome</condition>
  <condition>Progressive Supranuclear Palsy</condition>
  <condition>Behavioral Variant Frontotemporal Dementia</condition>
  <condition>Semantic Dementia</condition>
  <condition>Progressive Nonfluent Aphasia</condition>
  <condition>Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>Progressive supranuclear palsy</arm_group_label>
    <description>Observational Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticobasal syndrome</arm_group_label>
    <description>Observational Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Behavoral variant FTD</arm_group_label>
    <description>Observational Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semantic variant PPA</arm_group_label>
    <description>Observational Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-fluent variant PPA</arm_group_label>
    <description>Observational Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTD-motor neuron disease</arm_group_label>
    <description>Observational Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Observational Study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational Study</intervention_name>
    <arm_group_label>Progressive supranuclear palsy</arm_group_label>
    <arm_group_label>Corticobasal syndrome</arm_group_label>
    <arm_group_label>Behavoral variant FTD</arm_group_label>
    <arm_group_label>Semantic variant PPA</arm_group_label>
    <arm_group_label>Non-fluent variant PPA</arm_group_label>
    <arm_group_label>FTD-motor neuron disease</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood for biomarkers will be collected from participants for genetic testing. In addition,
      cerebrospinal fluid (CSF) will be collected to measure levels of different proteins, such as
      tau.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of progressive supranuclear palsy (PSP), corticobasal syndrome
        (CBS), semantic variant primary progressive aphasia (sv-PPA), non-fluent variant PPA
        (nfv-PPA), behavioral variant frontotemporal dementia (bvFTD) or FTD-motor neuron disease
        (FTD-MND).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have a reliable study partner who can provide an independent
             evaluation of functioning.

          -  Able to read, understand and speak English for neuropsychological testing.

          -  All subjects must meet one of these diagnostic criteria (A) probable behavioral
             variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic
             variant PPA and [18F]T807 negative (D) probable CBS: using current criteria for
             CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of
             Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy
             (NINDS-SPSP) (F) FTD-MND

          -  Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and
             MMSE score equal to or greater than 28

        Exclusion Criteria:

          -  Patients with clinical, imaging or CSF A beta/ tau profile consistent with AD

          -  History of traumatic brain injury, brain tumors, stroke or other neurological or
             psychiatric disorders that can explain symptoms will be excluded.

          -  Premenopausal women will be asked to consent to a pregnancy test prior to each scan as
             pregnant women will be excluded from study because of potential harm to fetus from PET
             study.

          -  Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal
             fragments or foreign objects in the eyes, skin or body.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria C Tartaglia, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto Western Hospital, UHN; Tanz CRND</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Namita Multani, MSc</last_name>
    <phone>416-507-6880</phone>
    <email>namita.multani@mail.utoronto.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toronto Western Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmela Tartaglia, MD</last_name>
      <phone>416-603-5483</phone>
      <email>carmela.tartaglia@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>November 10, 2016</last_update_submitted>
  <last_update_submitted_qc>November 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Carmela Tartaglia</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
    <mesh_term>Aphasia, Broca</mesh_term>
    <mesh_term>Primary Progressive Nonfluent Aphasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

